Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in Korea.
Brand Name : GV1001
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 30, 2021
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GemVax & Kael Reports Further Positive Data from GV1001 Phase II Alzheimer's Disease Trial
Details : GemVax's GV1001 Phase II trial evaluated the safety and efficacy of subcutaneous injection of GV1001 0.56 mg or 1.12 mg for six months in patients with moderate-to-severe Alzheimer's disease already receiving donepezil for more than three months, at 12 m...
Brand Name : GV1001
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 23, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The pivotal decision is based on an encouraging recent analysis of results from a Phase II trial of GV1001, completed last year in Korea and if granted would apply to a second Phase IIb trial in the US now planned for early 2021.
Brand Name : GV1001
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 06, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tertomotide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gemvax & Kael Expands GV1001 Patent To Cover COVID-19
Details : GV1001 has been proven to relieve the aforementioned conditions, as well as help boost immune system, in the preclinical trial phase.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 31, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?